In estrogen receptor (ER)-positive breast cancer, which comprises approximately 75% of all breast cancers [1], endocrine therapies targeting the ER or estrogen synthesis have been the standard adjuvant therapies [2–4]. This evidence concerns the gene ESR1 and breast carcinoma.